Generic pricing pressure persists
Management acknowledged continued high competition and pricing headwinds in the generics segment, which could pressure margins.
medium · management_commentary
Divi's Laboratories — Q4 FY25
Divis Laboratories reported a strong Q4 FY25 with PAT of INR 662 crore, up 23% YoY, driven by robust custom synthesis momentum and stable generic volumes despite pricing headwinds.
bullish
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Red Sea disruptions impacting logistics
Extended lead times of 2-3 weeks due to Red Sea rerouting are increasing freight costs and complicating supply chain planning.
medium · management_commentaryCustomer regulatory approval delays
Commercialization of new CS contracts depends on customer regulatory approvals, which could slip beyond the guided timeline.
medium · analyst_questionInventory normalization uncertainty
Inventory remains elevated at ~₹3,000 crore; management could not confirm if this level will sustain, posing working capital risk.
low · data_observation